Generic Celebrex Availability
Celebrex is a brand name of celecoxib, approved by the FDA in the following formulation(s):
CELEBREX (celecoxib - capsule; oral)
-
Manufacturer: GD SEARLE
Approval date: December 31, 1998
Strength(s): 100MG, 200MG -
Manufacturer: GD SEARLE
Approval date: August 29, 2002
Strength(s): 400MG [RLD] -
Manufacturer: GD SEARLE
Approval date: December 15, 2006
Strength(s): 50MG
Has a generic version of Celebrex been approved?
No. There is currently no therapeutically equivalent version of Celebrex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celebrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Substituted pyrazolyl benzenesulfonamides
Patent 5,466,823
Issued: November 14, 1995
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
Assignee(s): G.D. Searle & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically-acceptable salt thereof.Patent expiration dates:- November 30, 2013✓
- May 30, 2014✓
- November 30, 2013
-
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Patent 5,563,165
Issued: October 8, 1996
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
Assignee(s): G. D. Searl & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1##Patent expiration dates:- November 30, 2013✓
- May 30, 2014✓
- November 30, 2013
-
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Patent 5,760,068
Issued: June 2, 1998
Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S. & Docter; Stephen H. & Yu; Stella S.
Assignee(s): G.D. Searle & Co.
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: ##STR1## or a pharmaceutically-acceptable salt thereof.Patent expiration dates:- June 2, 2015✓
- December 2, 2015✓
- June 2, 2015
-
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder
Patent RE44048
Issued: March 5, 2013
Assignee(s): G.D. Searle LLC
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: or a pharmaceutically-acceptable salt thereof. A method of treating inflammation or an inflammation-associated disorder in a subject by administering a therapeutically-effective dose of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof, to the subject.Patent expiration dates:- June 2, 2015✓
- June 2, 2015✓
- June 2, 2015✓
- June 2, 2015✓
- June 2, 2015✓
- June 2, 2015✓
- December 2, 2015✓
- June 2, 2015
See also...
- Celebrex Consumer Information (Drugs.com)
- Celebrex Consumer Information (Wolters Kluwer)
- Celebrex Consumer Information (Cerner Multum)
- Celebrex Advanced Consumer Information (Micromedex)
- Celebrex AHFS DI Monographs (ASHP)
- Celecoxib Consumer Information (Drugs.com)
- Celecoxib Consumer Information (Wolters Kluwer)
- Celecoxib Consumer Information (Cerner Multum)
- Celecoxib Advanced Consumer Information (Micromedex)
- Celecoxib AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
